Executive leadership team
Oriol Casanovas, PhD.
Co-Founder & interim CEODr. Casanovas is an internationally renowned biomedical researcher with extensive knowledge and experience in basic and translational research focused on determining the consequences of adaptation and resistance to therapies against cancer.
Gabriela Jiménez, PhD.
Co-Founder & COODr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies BSM, EADA business school and IESE. She is experienced in business development, drug development and biomarker discovery.
Bart Huisken, MBA.
Co-Founder & Business and Financial StrategistStrategic advisor Co-founded 7 businesses
over 20+ years, Business Angel and NED
Advisor team
Itziar Canamasas, PhD.
Business Advisor & ChairwomanDr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School and IMD Business School.
Luis Correia, DPhil, MBA
Business StrategyFormer Roche executive with 20+ years in partnering, strategy, and investor relations.
Richard Roberts, PhD.
Medicinal Chemistry Advisor20+ years in drug development
Scott Wilhem
Product Development Strategic AdvisorFormer director of oncology discovery at Bayer
Mark Tebbe
Operational and Chemistry Advisor20+ years in drug development
Todd Snowden
IVD Strategic & Commercial Development Advisor25+ years in MedTech. IVD expert & biomarker lead
Research team
Our academic founders have played a key role in demonstrating that resistance to cancer therapy occurs in response to adaptive mechanisms of tumor cells.
We are part of the Program Against Cancer Therapeutic Resistance (ProCURE)
We research resistance mechanisms and tumor malignization
We are always looking for new talent to join our team